This is an investigator sponsor trial that we’ve been conducting for a while, and I’ve presented results from this before, but these are the final results, and we found a response rate actually very similar in our two cohorts, right around 30%, one was 30, the other was 32. These cohorts being the monotherapy cohort and the cohort of patients who are on a stable dose of ruxolitinib. So sotatercept just to back up a little bit is an activin receptor-ligand trap, a novel mechanism to combat anemia, in this case in myelofibrosis...
This is an investigator sponsor trial that we’ve been conducting for a while, and I’ve presented results from this before, but these are the final results, and we found a response rate actually very similar in our two cohorts, right around 30%, one was 30, the other was 32. These cohorts being the monotherapy cohort and the cohort of patients who are on a stable dose of ruxolitinib. So sotatercept just to back up a little bit is an activin receptor-ligand trap, a novel mechanism to combat anemia, in this case in myelofibrosis. The drug has been studied in MDS as well. And we found that it’s clearly active, it’s very safe. In some patients, they get a remarkable response, they even have to hold the drug for multiple cycles because the hemoglobin overshoots and you wait until it comes back down.
But of course, in others, it does not have much of an effect, but clearly, an active drug, novel mechanism, luspatercept which is sort of a counterpart of it, or I should say, close a cousin of sotatercept is the one being developed, and that’s already on the market for beta-thalassemia and MDS and is being developed for myelofibrosis. So this should be… This class of drugs, if not sotatercept, this class of drugs should be a very helpful addition to the arsenal for anemia and myelofibrosis. And so we hope to see luspatercept approved and available for MF patients.